BriaCell Therapeutics (TSE:BCT) Shares Down 4.2% – Here’s Why

BriaCell Therapeutics Corp. (TSE:BCT) shares dropped 4.2% during mid-day trading on Friday . The company traded as low as C$5.10 and last traded at C$5.21. Approximately 37,392 shares traded hands during mid-day trading, an increase of 2% from the average daily volume of 36,693 shares. The stock had previously closed at C$5.44.

BriaCell Therapeutics Stock Performance

The stock has a market cap of C$37.77 million, a P/E ratio of -0.15 and a beta of 2.15. The business’s 50-day moving average price is C$7.49 and its 200-day moving average price is C$11.61.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.